Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Equity Ratio (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Equity Ratio for 10 consecutive years, with 0.05 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 130.78% to 0.05 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.05 through Dec 2025, down 130.78% year-over-year, with the annual reading at 0.05 for FY2025, 130.78% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.05 at Ultragenyx Pharmaceutical, down from 0.01 in the prior quarter.
  • The five-year high for Equity Ratio was 0.66 in Q1 2021, with the low at 0.05 in Q4 2025.
  • Average Equity Ratio over 5 years is 0.28, with a median of 0.2 recorded in 2023.
  • The sharpest move saw Equity Ratio surged 780.18% in 2024, then crashed 130.78% in 2025.
  • Over 5 years, Equity Ratio stood at 0.61 in 2021, then crashed by 62.41% to 0.23 in 2022, then decreased by 19.02% to 0.18 in 2023, then fell by 8.01% to 0.17 in 2024, then plummeted by 130.78% to 0.05 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.05, 0.01, and 0.12 for Q4 2025, Q3 2025, and Q2 2025 respectively.